Incorporation of Digital Gene Expression Profiling for Cell-of-Origin Determination (Lymph2Cx Testing) into the Routine Work-Up of Diffuse Large B-Cell Lymphoma

Overview

Journal J Hematop

Publisher Springer

Specialty Hematology

Date 2021 Aug 27

PMID 34447482

Citations 9

Authors

Ryan S Robetorye

Colleen A Ramsower

Allison C Rosenthal

Tameson K Yip

Amy J Wendel Spiczka

Betty J Glinsmann-Gibson

Lisa M Rimsza

Affiliations

Soon will be listed here.

Abstract

Diffuse large B-cell lymphomas (DLBCL) represent a clinically heterogeneous group of lymphomas that are classified together based on similarities in morphology and immunophenotype. Gene expression profiling further classifies DLBCL into distinct molecular subgroups based on cell-of-origin (COO), including Germinal Center B-cell type, Activated B-cell type, and Unclassified type. COO assignment of DLBCL has important biological and prognostic significance, as well as emerging therapeutic implications. Herein, we describe the first clinical validation of a digital gene expression profiling assay (Lymph2Cx) to perform COO assignment in the routine work-up of DLBCL using formalin-fixed paraffin-embedded (FFPE) tissue sections and describe the results of 90 consecutive DLBCL cases analyzed prospectively by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA)-certified clinical molecular diagnostics laboratory.

Citing Articles

Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review.

Berhan A, Almaw A, Damtie S, Solomon Y Discov Oncol. 2025; 16(1):184.

PMID: 39954204 PMC: 11829893. DOI: 10.1007/s12672-025-01958-w.

Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma.

McCrury M, Swafford K, Shuttleworth S, Mehdi S, Acharya B, Saha D Mol Cancer Ther. 2023; 23(3):316-329.

PMID: 37816504 PMC: 10932871. DOI: 10.1158/1535-7163.MCT-23-0299.

Primary pulmonary intravascular large B‑cell lymphoma misdiagnosed as pneumonia: Four case reports and a literature review.

Zhu M, Chang Y, Fan H, Shi J, Zhu B, Mai X Oncol Lett. 2023; 25(6):234.

PMID: 37153040 PMC: 10161321. DOI: 10.3892/ol.2023.13820.

Sequencing therapy in relapsed DLBCL.

Flowers C, Odejide O Hematology Am Soc Hematol Educ Program. 2022; 2022(1):146-154.

PMID: 36485076 PMC: 9820056. DOI: 10.1182/hematology.2022000332.

Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels.

Carreras J, Roncador G, Hamoudi R Cancers (Basel). 2022; 14(21).

PMID: 36358737 PMC: 9657332. DOI: 10.3390/cancers14215318.

References

Ennishi D, Mottok A, Ben-Neriah S, Shulha H, Farinha P, Chan F . Genetic profiling of and in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017; 129(20):2760-2770. DOI: 10.1182/blood-2016-11-747022. View

Reinke S, Richter J, Fend F, Feller A, Hansmann M, Huttl K . Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining. Virchows Arch. 2018; 473(3):341-349. DOI: 10.1007/s00428-018-2367-4. View

Green T, Young K, Visco C, Xu-Monette Z, Orazi A, Go R . Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28):3460-7. DOI: 10.1200/JCO.2011.41.4342. View

Scott D, Wright G, Williams P, Lih C, Walsh W, Jaffe E . Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014; 123(8):1214-7. PMC: 3931191. DOI: 10.1182/blood-2013-11-536433. View

Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-23. PMC: 9103713. DOI: 10.1056/NEJMoa0802885. View

Coutinho R, Clear A, Owen A, Wilson A, Matthews J, Lee A . Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res. 2013; 19(24):6686-95. PMC: 4206944. DOI: 10.1158/1078-0432.CCR-13-1482. View

Reddy A, Zhang J, Davis N, Moffitt A, Love C, Waldrop A . Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017; 171(2):481-494.e15. PMC: 5659841. DOI: 10.1016/j.cell.2017.09.027. View

Czuczman M, Trneny M, Davies A, Rule S, Linton K, Wagner-Johnston N . A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2017; 23(15):4127-4137. PMC: 8171498. DOI: 10.1158/1078-0432.CCR-16-2818. View

Nowakowski G, Laplant B, Macon W, Reeder C, Foran J, Nelson G . Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2014; 33(3):251-7. DOI: 10.1200/JCO.2014.55.5714. View

10.

Scott D . Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?. Am Soc Clin Oncol Educ Book. 2015; :e458-66. DOI: 10.14694/EdBook_AM.2015.35.e458. View

11.

Johnson N, Slack G, Savage K, Connors J, Ben-Neriah S, Rogic S . Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28):3452-9. PMC: 3454768. DOI: 10.1200/JCO.2011.41.0985. View

12.

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

13.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

14.

Rosenwald A, Wright G, Chan W, Connors J, Campo E, Fisher R . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-47. DOI: 10.1056/NEJMoa012914. View

15.

Yoon N, Ahn S, Yoo H, Kim S, Kim W, Ko Y . Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. Oncotarget. 2017; 8(13):22014-22022. PMC: 5400642. DOI: 10.18632/oncotarget.15782. View

16.

Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Facchetti F . The clinicopathologic spectrum of mature aggressive B cell lymphomas. Virchows Arch. 2017; 471(4):453-466. DOI: 10.1007/s00428-017-2199-7. View

17.

Horn H, Ziepert M, Becher C, Barth T, Bernd H, Feller A . MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013; 121(12):2253-63. DOI: 10.1182/blood-2012-06-435842. View

18.

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

19.

Mareschal S, Ruminy P, Bagacean C, Marchand V, Cornic M, Jais J . Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. J Mol Diagn. 2015; . DOI: 10.1016/j.jmoldx.2015.01.007. View

20.

Staiger A, Ziepert M, Horn H, Scott D, Barth T, Bernd H . Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017; 35(22):2515-2526. DOI: 10.1200/JCO.2016.70.3660. View